[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369404-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369404-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","optimizing-til-therapy-for-uveal-melanoma-lessons-learned-and-unlearned-from-cutaneous-melanoma","Optimizing TIL therapy for uveal melanoma - lessons learned and unlearned from cutaneous melanoma","","Adoptive transfer of tumor infiltrating lymphocytes (TIL-ACT) is a personalized immunotherapy that activates and expands patient-derived tumor-resident T cells ex vivo, then delivers them with high-dose IL-2 after lymphodepleting chemotherapy. While FDA approval of lifileucel in 2024 established TIL-ACT for advanced cutaneous melanoma, its use in other solid tumors—especially poorly immunogenic cancers—is uncertain. This review traces TIL-ACT development in advanced cutaneous melanoma, then focuses on metastatic uveal melanoma by comparing key biology, guiding UM-specific TIL manufacturing, and outlining emerging precision biomarkers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/optimizing-til-therapy-for-uveal-melanoma-lessons-learned-and-unlearned-from-cutaneous-melanoma/369404/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/optimizing-til-therapy-for-uveal-melanoma-lessons-learned-and-unlearned-from-cutaneous-melanoma/369404.png","ImageObject",300,407,{"name":42,"@type":43},"Jake","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is TIL-ACT and how is it administered?","Question",{"text":63,"@type":64},"TIL-ACT uses ex vivo activation and expansion of tumor infiltrating lymphocytes, followed by infusion of a single expanded TIL dose with high-dose IL-2 after preparative lymphodepleting chemotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does uveal melanoma differ from cutaneous melanoma in immune response?",{"text":68,"@type":64},"Uveal melanoma is resistant to immune checkpoint inhibition, while studies indicate that many uveal melanoma metastases naturally contain TIL with potent autologous anti-tumor reactivity.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports using TIL-ACT for metastatic uveal melanoma?",{"text":72,"@type":64},"The review reports cancer regression in 35% of metastatic uveal melanoma patients after TIL-ACT, including individuals who are refractory to immune checkpoint inhibition, suggesting that tumor-specific immune cells can be exploited.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369404,1790216940,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084928904,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","IMMUNOTHERAPY  \n2025, VOL. 17, NO. 4, 283–291  \n[https://doi.org/10.1080/1750743X.2025.2478808](https://doi.org/10.1080/1750743X.2025.2478808)  \nREVIEW  \nOptimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma  \nShravan Leonard-Muralia,b,c,d and Udai S. Kammulaa,b,c  \naSolid Tumor Cellular Immunotherapy Program, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA; bDivision of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA; cDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, PA, USA; dDivision of Surgical Oncology, Department of Surgery, Allegheny Health Network, Pittsburgh, PA, USA  \nABSTRACT  \nAdoptive transfer of tumor infiltrating lymphocytes (TIL-ACT) is a personalized cancer therapy that harnesses the anti-tumor activity of tumor resident T cells through ex vivo activation and expansion. This therapy involves the infusion of a single dose of ex vivo expanded TIL together with high dose IL-2 following a preparative lymphodepleting chemotherapy. The United States Food and Drug Administration approved lifileucel in 2024 as the first autologous TIL product for patients with advanced cutaneous melanoma (CM), adding to the list of approved immunotherapies for this highly immunogenic cancer. However, the role for TIL-ACT in other solid tumors is unclear, especially for poorly immunogenic cancers with low tumor mutational burden. In this review, we describe the historical development of TIL-ACT, summarize the clinical results in advanced CM, and describe the novel application of TIL-ACT to metastatic uveal melanoma (UM), a prototypic immunotherapy-resistant solid tumor. We will highlight key biologic differences between CM and UM, their consequential influence on the manufacturing of UM-specific TIL products, and the development of novel biomarkers for precision TIL-ACT for metastatic UM.  \nPLAIN LANGUAGE SUMMARY  \nWhat is this review article about? Adoptive transfer of tumor infiltrating lymphocytes (TIL-ACT) is a personalized immunotherapy that was recently approved by the United States Food and Drug Administration for treatment of refractory advanced cutaneous melanoma (CM), a notably immunogenic cancer. However, its role in the treatment of poorly immunogenic solid tumors is unclear. Here, we describe the development of TIL-ACT for treatment of metastatic uveal melanoma (UM), a prototypic poorly immunogenic cancer.  \nWhat are the major findings? Unlike CM, UM is resistant to immune checkpoint inhibition (ICI) . However, studies have revealed that most UM metastases naturally harbor TIL with potent autologous anti-tumor reactivity. Ex vivo expansion and intravenous infusion of these TIL can mediate cancer regression in 35% of metastatic UM patients, including ICI refractory individuals. These findings establish that potent immune cells do exist within select UM metastases and that they can be exploited using TIL-ACT but not other forms of immunotherapy. Biomarkers enabling identification of UM-specific TIL are being developed to improve personalized TIL-ACT for UM patients.  \nHow will this have broad impact in the field of immunotherapy? Development of TIL-ACT for metastatic UM provides novel therapeutic options for this cancer with unmet medical need. These translational efforts may serve as a blueprint for the treatment of other immunotherapy-resistant cancers.  \nARTICLE HISTORY  \nReceived 9 December 2024 Accepted 10 March 2025  \nKEYWORDS  \nUveal melanoma; immune exclusion; immunotherapy; immune checkpoint inhibition; adoptive cell therapy; tumor infiltrating lymphocytes  \n1. Introduction  \nAdoptive cell therapy (ACT) using autologous tumor infiltrating lymphocytes (TIL) is a personalized cancer immunotherapy strategy that targets both shared and unique antigens expressed by a patient’s tumor. This treatment evolved from the fundamental observation that tumor reactive lymphocytes can be found infiltrating","cbCaiaMNDvRLZKGw","https://ap.wps.com/l/cbCaiaMNDvRLZKGw","pdf",865420,"English","# Introduction\n# Article highlights\n# Plain language summary\n# Article history\n# Keywords","[{\"question\":\"What is TIL-ACT and how is it administered?\",\"answer\":\"TIL-ACT uses ex vivo activation and expansion of tumor infiltrating lymphocytes, followed by infusion of a single expanded TIL dose with high-dose IL-2 after preparative lymphodepleting chemotherapy.\"},{\"question\":\"How does uveal melanoma differ from cutaneous melanoma in immune response?\",\"answer\":\"Uveal melanoma is resistant to immune checkpoint inhibition, while studies indicate that many uveal melanoma metastases naturally contain TIL with potent autologous anti-tumor reactivity.\"},{\"question\":\"What evidence supports using TIL-ACT for metastatic uveal melanoma?\",\"answer\":\"The review reports cancer regression in 35% of metastatic uveal melanoma patients after TIL-ACT, including individuals who are refractory to immune checkpoint inhibition, suggesting that tumor-specific immune cells can be exploited.\"}]","Optimizing TIL therapy for uveal melanoma - lessons learned and unlearned from cutaneous melanoma | PDF",1790182449,23,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2eab2d93a50b6e115d8f8abd098e6323.webp",983,1280,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb8639b99a493f2d500c1e4b52dd4c08.webp",982,1278,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8374734873f9a15d73190597f5505199.webp",981,1277,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1fd0e5c587f21605e56db5663775e01b.webp",980,1276]